News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Tocagen June 2015 Newsletter


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

This edition of the Tocagen newsletter shows that the company has a lot of confidence in their brain tumor treatment. They added Dr. Das as vice president of clinical development and medical affairs. She played a huge part in the FDA approval process for Avastin for GBMS.

They also got approval from the FDA to start a newtrial which if successful will allow them to apply for FDA approval. The newsletter also has links to a lot of presentations made about this treatment, and also mentions the Musella Foundation! (We gave a grant to support preclinical testing of Toca 511 with 5-ALA or tumor treating fields!)

 (Disclaimer: Tocagen is a sponsor of our organization)



Website: http://www.tocagen.com/tocagen-newsletter-june-2015/

Posted on: 07/01/2015

http://www.tocagen.com/tocagen-newsletter-june-2015/

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740